TEWKSBURY, MA – January 13, 2020— Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the first Japanese patients were randomized in Toyama and Hyogo under a clinical trial authorization from the Pharmaceutical and Medical Device Agency (PMDA) in the REDUCE LAP-HF II trial. The Corvia InterAtrial […]
TEWKSBURY, MA – October 9, 2019— Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its InterAtrial Shunt Device (IASD) for heart failure.The IASD is the world’s first transcatheter device […]
Corvia Medical Enters Into Agreement With Edwards Lifesciences, The Global Leader In Structural Heart Innovation
Corvia Medical Announces Strong Positive One-Year Data From Reduce LAP-HF I Randomized, Sham-Controlled Clinical Trial
Corvia Medical Announces Enrollment of First Patients in Pivotal Trial of the IASD® System II for the Treatment of Heart Failure
Corvia Medical Announces Strong Positive One-Year Data from Reduce LAP-HF Clinical Study
Corvia Medical Announces CE Mark Approval and Enrollment of First Patients in Randomized Clinical Study
Corvia Medical Receives IDE Approval for REDUCE LAP-HF I Clinical Study & Announces Agreement with Strategic Partner for Exclusive Option to Purchase Company
DC Devices Completes Enrollment In Clinical Trial of the First Transcatheter Device to Treat Diastolic Heart Failure; Announces Name Change to Corvia Medical
DC Devices Closes $34m Series D Financing to Complete Clinical Evaluation of the First Transcatheter Device to Treat Diastolic Heart Failure
